Product Overview
Composition
Composition for 1 ml:
Ethylmethylhydroxypyridine succinate - 50 mg
Water for injection - up to 1 ml.
pharmachologic effect
Mexiprim belongs to heteroaromatic antioxidants.
Has a wide range of pharmacological activity: increases the body's resistance to stress, exhibits anxiolytic effect, not accompanied by drowsiness and muscle relaxant effect;
possesses nootropic properties, prevents and reduces learning and memory disorders arising from aging and exposure to various pathogenic factors;
has an anticonvulsant effect; exhibits antioxidant and antihypoxic properties; increases concentration and performance; weakens the toxic effect of alcohol.
The drug improves the metabolism of brain tissues and their blood supply, improves microcirculation and rheological properties of blood, reduces platelet aggregation.
It stabilizes the membrane structures of blood cells (erythrocytes and platelets). It has a hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins.
The mechanism of action of Mexiprim is due to its antioxidant and membrane-protective action.
It inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity.
Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA,
acetylcholine), which enhances their ability to bind to ligands, helps to maintain the structural and functional organization of biomembranes, transport neurotransmitters and improve synaptic transmission.
Mexiprim increases the content of dopamine in the brain.
It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.
Pharmacokinetics The maximum plasma concentration of Mexiprim is in the range from 50 to 100 ng / ml.
The half-life of Mexiprim and the average retention time of the drug in the body are 4.7-5.0 hours and 4.9-5.2 hours, respectively.
Mexiprim in the human body is extensively metabolized to form its glucuronoconjugated product.
On average, 0.3% of the unchanged drug and 50% of the administered dose are excreted in the urine over 12 hours.
The most intense Mexiprim and its glucuronoconjugate are excreted during the first 4 hours after taking the drug.
Indicators of excretion in the urine of Mexiprim and its conjugated metabolite have significant individual variability.
Indications
- Acute disorders of cerebral circulation (as part of complex therapy);
- Encephalopathy;
- Vegeto-vascular dystonia;
- Anxiety states in neurotic and neurosis-like states;
- Mild cognitive disorders of various origins (psychoorganic and asthenic syndromes, consequences of craniocerebral trauma, atherosclerosis, senile and atrophic processes, neuroinfections and intoxication);
- Memory disorders and intellectual disability in the elderly;
- Exposure to extreme (stress) factors;
- Withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
- Acute intoxication with antipsychotic drugs.
Contraindications
- acute liver dysfunction;
- acute renal dysfunction;
- childhood;
- pregnancy;
- lactation (breastfeeding);
- hypersensitivity to drug components.
Side effects
From the digestive system: nausea, dry mouth.
Others: drowsiness, allergic reactions.
Interaction
With the simultaneous use of Mexiprim enhances the effect of anxiolytics from the benzodiazepine group, antiparkinsonian (levodopa) and anticonvulsants (carbamazepine).
Mexiprim reduces the toxic effects of ethanol.
How to take, course of administration and dosage
Mexiprim is administered i / m or i / v (jet or drip). To prepare a solution for infusion, the drug should be diluted with isotonic sodium chloride solution.
Doses are selected individually depending on the pathology and severity of the patient's condition. The initial dose is 50-100 mg 1-3 times / day. In the future, it is possible to increase the dose until a therapeutic effect is obtained. The maximum daily dose is 800 mg.
Jet Mexiprim is injected slowly, over 5-7 minutes, drip - at a rate of 40-60 drops / min.
In the treatment of acute disorders of cerebral circulation, Mexiprim is used in complex therapy in the first 2-4 days intravenous drip at a dose of 200-300 mg 1 time / day, then 100 mg intramuscularly 3 times / day. The duration of treatment is 10-14 days.
In case of discirculatory encephalopathy in the decompensation phase, Mexiprim should be administered intravenously by jet or drip at a dose of 100 mg 2-3 times / day for 14 days. Then the drug is administered intramuscularly at 100 mg / day for the next 2 weeks. For the course prevention of discirculatory encephalopathy, the drug is administered intramuscularly at a dose of 100 mg 2 times / day for 10-14 days.
In case of mild cognitive impairment in elderly patients and in case of anxiety disorders, the drug is used intramuscularly in a daily dose of 100-300 mg for 14-30 days.
With alcohol withdrawal syndrome, Mexiprim is administered at a dose of 100-200 mg IM 2-3 times / day or IV drip 1-2 times / day for 5-7 days.
In case of acute intoxication with antipsychotic drugs, the drug is administered intravenously at a dose of 50-300 mg / day for 7-14 days.
Overdose
Symptoms:
sleep disturbance (insomnia, in some cases, drowsiness).
Treatment:
As a rule, not required - symptoms disappear on their own within 24 hours.
In severe cases of insomnia, sleeping pills are recommended.
Special instructions
Use in pediatrics
Adequate and strictly controlled clinical studies of the safety of using the drug Mexiprim in children have not been conducted, therefore, the drug should not be prescribed to this category of patients.
Release form
Solution for intravenous and intramuscular administration is colorless or slightly yellowish, transparent.
